The provisions relating to confidential third-party rebates will not come into force at the same time as the other provisions.

On June 3, 2020, a proposed class action was commenced against over 50 generic drug manufacturers.

The Canadian Patent Office (CIPO) has advised that as of January 14, 2025, it had granted patents for which final fees were processed in the old system.

The Federal Court of Appeal ("FCA") has ordered a new trial in the STELARA litigation. As reported in the January 20, 2014 issue of IP Update — Canada, earlier this year Justice Hughes of the Federal Court concluded that Janssen Inc (Janssen)'s antibody drug STELARA (ustekinumab) ..

The Federal Court of Appeal recently dismissed a motion brought by the Minister of Health (the Minister) for stay of a judgment of the Federal Court...

C'est aujourd'hui même que le gouvernement de l'Allemagne a ratifié l'Entente sur la Juridiction Unifiée du Brevet (EJUB), permettant ainsi la mise en branle de plusieurs changements...

In many countries, during trade-mark prosecution, a letter of consent can be filed to overcome a citation of another mark.

We have previously written about the benefits of licensing as a way to get the drug remdesivir quickly deployed during the COVID-19 pandemic.

The Canadian Intellectual Property Office and the European Patent Office have started their Patent Prosecution Highway pilot program.

In Adobe Systems Incorporated, Microsoft Corporation and Rosetta Stone Ltd. v. Dale Thompson, the Federal Court recently took another significant step in addressing the problem of sale of pirated software in Canada.

Eli Lilly and Company sued the government as a result of the invalidation, by Canadian courts, of the patents that protected Lilly's drugs Strattera® and Zyprexa®.

Health Canada is proposing to restrict the marketing of food containing certain levels of saturated fat, sugars or sodium ("unhealthy" food) to children under the age of 18.

On June 19, 2025, Canada's Drug Agency (CDA) opened a public consultation on a proposed process for preparing a list of essential prescription drugs and related products.

On April 15, 2025, Canada's Drug Agency (CDA) released its new five-year strategic plan, Insight to Impact 2025-2030. Formerly the Canadian Agency for Drugs and Technologies in Health (CADTH), this is the CDA's first strategic plan.

On January 29, 2026, the Minister of Health announced Anie Perrault, former Vice-Chairperson, as Chairperson of the Patented Medicine Prices Review Board (PMPRB) until August 9, 2028.

On July 17, the Canadian Patent Office launched MyCIPO Patents. The highly anticipated new database and filing system allows for immediate application number confirmation when filing online...

On August 8, 2025, the Federal Court of Appeal (FCA) determined that the Minister of Health's decision to list Canadian Patent No. 2,970,315 on the Patent Register eight days...

Traditional cultural expressions and knowledge are invaluable assets to Indigenous communities, yet they often do not align with the protections offered by Western IP systems.

Over ten years have passed since the Federal Court of Appeal (FCA) flagged the patentability of methods of medical treatment as being worthy of full consideration by the Supreme Court of Canada. This issue has finally come before the Court.

There are multiple ongoing class actions in Canada against pharmaceutical companies related to Opioid Use Disorder (OUD) and its effects. While these proceedings are all currently in their early stages...